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Clonidine hydrochloride (an alpha-2 adrenergic agonist) and 
naltrexone hydrochloride (an opioid antagonist), given in 
combination, provided a safe and effective treatment of abrupt 
opioid withdrawal over 5 days in an outpatient/day setting. 12 
of 14 (86%) heroin users successfully withdrew from opioids and 
simultaneously initiated naltrexone maintenance. Patients came 
to clinic for the morning of day 1, spent 8 hours at clinic on 
both days 2 and 3, and one hour at clinic on both days 4 and 5. 
A flexible treatment regimen was defined that titrated drug 
dosages in response to symptoms. Clonidine significantly reduced 
blood pressure without clinical problems. One patient developed 
signs of clonidine overdose following withdrawal from the study 
and ingestion of a variety of other medications. A naloxone 
challenge test was used to verify and quantify opioid dependence; 
correlations were observed between challenge test score and 
medication doses given, and between test score and patient 




Physicians have long sought to alleviate the symptoms of 
opioid withdrawal. The opioid withdrawal syndrome, together with 
the phenomenon of tolerance, makes manifest "opioid dependence" 
(APA 1980), defined as the biological changes or "neuroadapta¬ 
tion" (Edwards 1981) that occur following chronic opioid adminis¬ 
tration. Opioid abuse, characterized by inability to reduce or 
stop opioid use despite consequent impairment of social or occu¬ 
pational functioning (APA 1980), is often accompanied by opioid 
dependence. Successful withdrawal treats dependence, but does 
not prevent relapse (and hence is not a sufficient treatment of 
opioid abuse or "addiction"). Nevertheless, withdrawal is an im¬ 
portant element in the therapy of addiction, and is the first 
step towards definitive treatment of opioid abuse (except for pa¬ 
tients entering methadone maintenance). 
Since the late nineteenth century a variety of withdrawal 
treatments have been advocated, including belladonna or scopala- 
mine intoxication, sodium thiocyanate, "bromide sleep treatment," 
ECT, and "hibernation therapy" (Kleber 1982). These methods have 
been endorsed, practiced, and then discarded when they proved to 
be ineffective and often more dangerous than the condition they 
set out to alleviate. Since 1948, methadone, a long acting 
opioid agonist, has been used as a substitute opioid that is ad- 
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ministered to the opioid dependent patient in gradually decreas¬ 
ing daily doses. Methadone is usually administered over five to 
twelve days for the treatment of heroin withdrawal (Kleber 1982). 
This method attenuates symptoms while prolonging the course of 
withdrawal. 
Methadone treatment of heroin withdrawal has been tried in 
both inpatient and outpatient settings, and over various time 
courses, in an attempt to improve the efficacy of therapy. Wil¬ 
son, et al administered a ten day course of methadone to ten in¬ 
patients and thirty outpatients. One inpatient (10%) and six 
outpatients (20%) completed the protocol, and no inpatients (0%) 
and two outpatients (7%) remained drug-free following treatment. 
The authors concluded that there was no significant difference 
between approaches (Wilson 1975). Outpatient trials employing 
seven day and ninety day protocols have reported successful with¬ 
drawal rates of 32% and 13%, respectively (Silsby 1974) (Wilson 
1974). At six months, 9.5% and 0% of patients in these two stud¬ 
ies were drug free. Dorus, et al compared an FDA-mandated twen¬ 
ty-one day methadone taper with an eighty-four day taper under 
double blind conditions. They found that the more gradual taper 
was more successful, resulting in a 35% rate of successful detox¬ 
ification and abstinence for one week. One year later, 16% of 
the patients that underwent the eighty-four day taper were absti¬ 
nent (Dorus 1981) (Dorus 1982). None of the patients in their 
twenty-one day group remained opiate free for even ninety days. 
A slower methadone taper decreases the symptoms of withdrawal for 
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both heroin users (Dorus 1981) and methadone maintained patients; 
the latter achieved a 53% rate of successful detoxification with 
a thirty week methadone taper (Senay 1977). But despite protocol 
innovations, these studies have concluded that methadone treat¬ 
ment of heroin dependence is successful in less than 40% of cas¬ 
es, and is an even less successful treatment of heroin abuse. 
Investigators have continued to search for methods of allevi¬ 
ating the opioid withdrawal syndrome that are more rapid and more 
effective than methadone detoxification, and that do not involve 
use of opioid agonists or other addicting substances. In 1964 
Berle and Nyswander treated withdrawal over two to four weeks 
with a combination of meprobamate, chlorpromazine, and glutethi- 
mide; fifty-three of their two hundred sixty-eight patients (20%) 
withdrew successfully. Opiate antagonists have been used to 
treat withdrawal by shortening the length of the abstinence syn¬ 
drome (Blachly 1975) (Kuiland 1975) (Resnick 1977). While mark¬ 
edly compressing the time of withdrawal, this treatment intensi¬ 
fied withdrawal symptoms, even when symptomatic medications such 
as atropine and diazepam were added. Recently, clonidine, an im¬ 
idazoline alpha-2 adrenergic agonist used as an antihypertensive, 
has been demonstrated to effectively suppress the signs and symp¬ 
toms of opioid withdrawal, with reported success rates as high as 
80% with methadone withdrawal (Charney 1981) and 36% with heroin 
withdrawal (Washton 1980b). 
- 4 - 

While opioid withdrawal affects brain function in a variety of 
ways (Redmond 1984), perhaps its most prominent effect is on cen¬ 
tral nervous system noradrenergic function. Clonidine alters the 
opioid withdrawal syndrome by modulating central nervous system 
noradrenergic activity. In 1959 Gunne demonstrated that total 
brain norepinephrine (NE) decreased during opioid withdrawal, 
suggesting that withdrawal was associated with increased NE re¬ 
lease (Gunne 1959). Vasques, in 1974, found that chronic mor¬ 
phine administration led to a disuse hypersensitivity in central 
noradrenergic systems (Vasques 1974). Opioids depress the firing 
rate of the locus coeruleus (LC), the largest central noradrener¬ 
gic nucleus (Korf 1974) (Bird 1977); prolonged opioid administra¬ 
tion and concommitant LC depression result in enhanced numbers of 
alpha-2 and beta adrenergic binding sites in LC projection areas 
(Hamburg 1981) (Llorens 1978). Opioid withdrawal is associated 
with central noradrenergic hyperactivity as reflected by de¬ 
creased brain norephinephrine levels (Gunne 1959) and increased 
norepinephrine metabolite levels (Crawley 1979). Clonidine, an 
alpha adrenergic agonist that diminishes NE release by binding 
presynaptically to alpha-2 receptors, reverses the increased no¬ 
repinephrine turnover seen during morphine withdrawal in rats 
(Laverty 1980). 
Using single-cell recording and microiontophoretic techniques, 
Aghajanian investigated the role of clonidine and the LC in 
opioid withdrawal. He found that naloxone increased LC activity 
in morphine dependent rats but not in control rats. Using con- 
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trol rats, he subsequently demonstrated that both morphine and 
clonidine suppress noradrenergic activity in the LC. Naloxone 
abolishes morphine-induced suppression, but does not abolish clo¬ 
nidine ' s suppressive effect. Piperoxane abolishes clonidine's 
suppressive effect but does not abolish morphine's suppressive 
effect. These data indicate that morphine acts at the LC by 
binding to opioid receptors, while clonidine's actions are medi¬ 
ated by alpha adrenergic receptors. Finally, in morphine depen¬ 
dent rats, he demonstrated that both morphine and clonidine could 
suppress naloxone-induced increases in LC activity; naloxone 
could override morphine's suppressive effect, but could not over¬ 
ride clonidine's suppressive effect (Aghajanian 1978). In mor¬ 
phine dependent rats, clonidine attenuates naloxone-precipitated 
NE turnover in a dose related fashion (Laverty 1979). These data 
established that opioid withdrawal provokes central noradrenergic 
hyperactivity, and that this hyperactivity can be reversed not 
only by morphine acting at opioid receptors, but by clonidine 
acting at alpha-2 receptors in the LC. Furthermore, clonidine's 
effect is not affected by naloxone. Thus a model of overlapping 
receptor populations in the LC has emerged that accounts for clo¬ 
nidine ' s antiwithdrawal effects. 
Clonidine has been shown to alter the symptoms and physiologi¬ 
cal signs of opioid withdrawal in animals. In morphine dependent 
rats, clonidine inhibits naloxone-induced escape attempts and 
"wet body shakes" (Tseng 1975), prevents weight loss and suppres¬ 
sion of conditioned behavior (Sparber 1978), and antagonizes na- 
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loxone-induced increases in mean arterial pressure (Buccafusco 
1983). Redmond correlated stimulation of the LC with behavioral 
observations in monkeys (Redmond 1976) (Redmond 1977) (Redmond 
1978) (Redmond 1981), suggesting that the central noradrenergic 
axis in large part mediates opioid withdrawal. 
Clonidine has, in fact, been used successfully to ameliorate 
withdrawal symptoms and to detoxify methadone maintained patients 
(Gold 1978a) (Uhde 1980) (Gold 1980) (Washton 1980a) (Washton 
1980b). Success rates of 70% (Washton 1980b) and 80% (Charney 
1981) have been reported in trials using clonidine for treatment 
of abrupt methadone withdrawal. In double blind, placebo cont¬ 
rolled studies clonidine has been shown to be more effective than 
placebo (Gold 1978b) and as effective as a twenty day methadone 
taper (Washton 1981) in alleviating methadone withdrawal symptoms 
and enabling complete detoxification. Clonidine treatment of 
heroin withdrawal is less well studied. Washton, who treated 
both heroin users and methadone maintained patients with cloni¬ 
dine, found that four of eleven (36%) heroin users and thirty- 
five of forty-nine (70%) methadone patients successfully remained 
opioid free for ten days (Washton 1980b). Clonidine treatment of 
heroin withdrawal takes seven to eight days, while methadone 
withdrawal requires ten to fourteen days. 
Clonidine has been used to treat withdrawal in an outpatient 
setting. At Yale, over one hundred methadone maintained patients 
have been withdrawn.using clonidine on an outpatient basis with- 
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out medical complications. The withdrawal symptoms of anxiety, 
restlessness, insomnia, and muscular aching are most refractory 
to clonidine and are reported to some degree by the majority of 
patients. 
The primary acute side effects of clonidine therapy are seda¬ 
tion and hypotension; as insomnia and hypertension are symptoms 
of withdrawal, neither side effect routinely interferes with 
therapy. Washton reported that, among a series of seventy outpa¬ 
tients, six "experienced unacceptable dizziness and/or sedation 
while taking only 0.3 mg/day of clonidine" (Washton 1980). Clo¬ 
nidine doses given to outpatients at Yale have been tapered or 
held if diastolic blood pressure dropped below 55, or systolic 
pressures were lower than 85. Charney, et al reported that, 
among twenty-five inpatients receiving peak clonidine doses of 16 
microg/kg/day, standing blood pressure was reduced by as much as 
17 +-13/8 +-11, without "producing clinical problems" (Charney 
1981). 
One drawback of both methadone taper and clonidine treatment 
is the time required to complete therapy. Long duration of mild 
withdrawal symptoms affords greater opportunity for treatment 
failure, with patients resuming opioid use. Thus clonidine has 
been paired with opioid antagonists that precipitate an abrupt 
opioid withdrawal syndrome (Riordan 1980), in an effort to short¬ 
en the duration of withdrawal while maintaining clonidine's bene¬ 
ficial effects. The first clinical trial of clonidine in combi- 
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nation with an antagonist used repeated naloxone injection 
(Riordan 1980); a second utilized naltrexone, an antagonist that 
is administered orally (Charney 1982). 
Naltrexone is a potent, long-acting narcotic antagonist used 
clinically to help maintain patients opioid-free after detoxifi¬ 
cation from methadone. It is an essentially pure narcotic antag¬ 
onist, that is, it does not possess "agonistic" or morphine-like 
properties characteristic of some other narcotic antagonists 
(Martin 1973). In the absence of narcotics or agonist effects it 
exhibits essentially no pharmacologic activity (Hollister 1981). 
Former addicts beginning naltrexone report side effects indistin¬ 
guishable from those of placebo, after a ten day period marked by 
loss of appetite and tiredness in 20% of subjects (Brahen 1977). 
There is some evidence that patients maintained on naltrexone 
have less subjective craving for heroin because of naltrexone 
therapy (Sideroff 1978) (Judson 1981). 
In the presence of physical dependence on narcotics, naltrex¬ 
one and other opioid antagonists induce an abrupt withdrawal syn¬ 
drome (Blachly 1975) (Kuiland 1975) (Resnick 1977) by altering 
central noradrenergic activity. Naloxone blocks opioid receptors 
on the LC and so increases LC firing rates in morphine-dependent 
animals (Aghajanian 1978) and rapidly reverses morphine-induced 
increases in the number of brain alpha-2 and beta adrenergic 
binding sites (Hamburg 1981) (Cedarbaum 1977). This rapid change 
in binding site numbers may account for the ability of naltrexone 
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to shorten the time course of the opioid withdrawal syndrome 
(Charney 1982). 
Clonidine and naltrexone have been used in combination on an 
inpatient basis to induce abrupt and safe withdrawal from metha¬ 
done over six days (Charney 1982). Ten of eleven patients who 
began a study conducted at the Connecticut Mental Health Center 
successfully detoxified from methadone; the eleventh left the 
study on the second day, after receiving the first dose of nal¬ 
trexone and experiencing some discomfort. The clonidine-naltrex- 
one regimen had three stages. On day 1, opioids were withheld 
and only clonidine given; on days 2 and 3, naltrexone was intro¬ 
duced and increasingly higher doses were given in combination 
with increasing doses of clonidine; and on days 4,5 and 6 naltre¬ 
xone doses plateaued at maintenance levels while clonidine doses 
fell to zero. The first stage, day 1, allowed time to observe 
the patients response to and tolerance of clonidine. During the 
second stage withdrawal was precipitated and symptoms ameliorated 
with higher doses of clonidine (2.9 +- .8 mg/day on day 2, 2.3 +- 
.6 mg/day on day 3). Clonidine doses were increased as needed to 
suppress withdrawal symptoms as rated by an abstinence rating 
scale. Clonidine effectively suppressed the symptoms naltrexone 
usually induces in a withdrawing addict; when compared to a pre¬ 
vious study that used clonidine alone to treat withdrawal (Char¬ 
ney 1981) patient discomfort was found to be lower with the clo- 
nidine-naltrexone regimen. During the third stage, naltrexone 
doses no longer elicited discomfort, clonidine doses fell off 
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rapidly, and no clonidine was required after day 5 or 6. Pa¬ 
tients wishing to be maintained on naltrexone continued to re¬ 
ceive maintenance doses of naltrexone without withdrawal symptoms 
or need for clonidine. Thus naltrexone induction took place as a 
part of withdrawal. 
Although this technique appeared to be effective on an inpa¬ 
tient basis, it was not evident that it could be done safely and 
effectively on an outpatient basis. Potential drawbacks of out¬ 
patient treatment include the danger of hypotension and sedation 
sometimes seen with clonidine therapy, the possibility of concur¬ 
rent illicit drug use, and patient compliance with clonidine dos¬ 
age schedules. Nevertheless, outpatient treatment of opioid 
withdrawal is desirable. Clearly, outpatient treatment is less 
expensive than inpatient treatment, and places less strain on 
limited medical resources. Outpatient therapy allows patients 
with jobs and other responsibilities to continue their employ¬ 
ment. Since it does not offer the useful but temporary shelter 
from the "drug culture" that inpatient treatment gives, relapse 
and treatment failure may be more likely in the outpatient set¬ 
ting. Long term relapse rates may not differ, however, since if 
the addict can withdraw from the social accoutrements of drug use 
while withdrawing from opioids, his prognosis may be better. The 
study described in this paper was designed to investigate the ef¬ 




Rapid outpatient detoxification, with simultaneous naltrexone 
induction, is desirable not only for patients maintained on me¬ 
thadone but for "street addicts" who use heroin and other opioids 
illicitly. This study was designed to enroll both types of 
opioid users. The degree of a street addict's opioid dependence 
is difficult to determine because of unreliable histories and the 
inconstant opioid concentrations found in street drugs. (For 
this reason, all clonidine research studies at Yale have been 
performed on methadone maintained patients whose daily intake of 
opioids was known.) As mentioned above, Washton and associates 
used clonidine on an outpatient basis with heroin addicts and 
found that 36% completed detoxification; they estimated depen¬ 
dence based on dollars spent on heroin per day, and found that 
patients with high estimates tended to be dissatisfied with the 
efficacy of the experimental regimen (Washton 1980). To avoid 
the subjectivity of this approach, we studied heroin addicts by 
quantifying their degree of physical dependence with a naloxone 
challenge test. From 3% to 33% of patients receiving a naloxone 
challenge in previous reports have had a negative test (Blachly 
1973) (Judson 1980), indicating that they were not opioid depen¬ 
dent and did not need methadone maintenance or a pharmacological 
regimen for withdrawal. The test we used, described by Wang and 
his associates in 1974 and modified in 1977 and 1982 (Wang 1974) 
(Weisen 1977) (Wang 1982), rates objective symptoms of withdraw¬ 
al, giving more weight to symptoms that appear rapidly. Weisen 
has demonstrated a significant correlation between test score and 
12 

appropriate initial methadone maintenance doses in 210 subjects 
(r=.77, p<0.01) (Weisen 1977), and this test can now be used to 
assess patients seeking methadone maintenance in order to assign 
initial methadone doses. The test accurately quantifies the se¬ 





The patient sample comprised ten men and seven women treated 
by the Substance Abuse Treatment Unit of the Connecticut Mental 
Health Center, New Haven. Mean age was 29.3 years (+-5.6) and 
mean duration of opioid use was 7.4 years (+-4.9). Patients were 
to be drawn from two populations. One group was to consist of 
members in good standing of a methadone maintenance program, 
maintained for at least three months and on a methadone dose of 
20 to 25 mg for at least one week prior to entering the study. 
Only one patient entered this treatment group. The second group 
consisted of self-professing opioid users who had not been en¬ 
rolled in a methadone maintenance program within the prior three 
months. Patients in this treatment group were required to under¬ 
go a naloxone challenge test. Sixteen patients entered this 
group during the duration of the study. All used heroin; over 
half of the sixteen abused other drugs as well. Four used in¬ 
travenous cocaine, five regularly purchased methadone, most 
smoked marijuanana, and two abused benzodiazapenes. 
All patients were in good health as evidenced by a medical 
history, physical examination, CBC, urinalysis, EKG, and SMA-12 
in the week prior to their inclusion in the study. All patients 
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gave informed written consent for their participation in the re¬ 
search protocol. Candidates were ruled out based on the follow¬ 
ing exclusionary criteria: 
1. Younger than 18 years or older than 45 years. 
2. Systolic blood pressure greater than 165, or diastolic 
pressure greater than 110, or ongoing medical treatment for 
hypertension. 
3. Current treatment for other medical conditions requiring 
ongoing medication. 
4. Treatment with tricyclic antidepressants, MAO inhib¬ 
itors, or phenothiazines during the two weeks prior to par¬ 
ticipation. 
5. Allergy to imidazoline drugs. 
6. History of acute or chronic active hepatitis, cardias 
arrythmias, rheumatic fever, sinus bradycardia of less than 
50 bpm, renal or metabolic diseases. 
7. Personal history of severe psychiatric disorder (e.g., 
major psychotic episode, schizophrenia, psychotic depres¬ 
sion, bipolar affective disorders.) 
8. Pregnancy. (All women included in the study has a neg¬ 
ative B-HCG test within one week of inclusion in the study.) 
During the week prior to participation in the study, all sub¬ 
jects completed the Beck Depression Inventory, the SCL-90, the 
Spielberger State Anxiety Index, and the Rotter Internal/External 




Patients received one day of clonidine followed by four to 
five days of combination clonidine and naltrexone therapy. Clo¬ 
nidine was administered t.i.d. with supplementary doses on days 
1, 2, and 3. Patients received naltrexone in four divided doses 
on days 2 and 3, and then in one or two doses on day 4 and in one 
dose on day 5. The treatment schedule was flexible, and was de¬ 
signed to produce minimum discomfort for the patient. 
Patients came to clinic daily at 8-9 am to receive medication, 
answer questionaires, and have their blood pressure monitored. 
On the second and third days of the study patients were required 
to remain in clinic from 8:30 am to 4:30 pm so that their with¬ 
drawal symptoms could be followed, naltrexone doses adjusted, and 
supplementary clonidine given as indicated. Patients were not 
allowed to work on the second and third days, and were not al¬ 
lowed to drive on the first three days. While in clinic, blood 
pressures were monitored before, 60 minutes after, and 120 min¬ 
utes after each clonidine dose. Patients took prescribed cloni¬ 
dine home with them (usually including a 0.1 to 0.2 mg "prn" 
dose), but were required to return extra pills the following 
morning. 
Clonidine was given daily at 8-9 am, 2 pm, and 8 pm. The lat¬ 
ter two doses could be taken at home. On the first day patients 
received only clonidine. Subjects not entering the study from a 
methadone maintenance program underwent a naloxone challenge test 
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on the morning of the first day (see below). On days 1, 2, and 3 
additional doses were given as needed to suppress symptoms of 
withdrawal; clonidine was given if the patient had 5 or more of 
the 17 signs and symptoms of withdrawal included in our absti¬ 
nence rating scale. On days 4 and 5 no supplementary clonidine 
was prescribed. No clonidine was required after day 6. Cloni¬ 
dine doses were tapered or held if standing systolic blood pres¬ 
sure was less than 80 or diastolic pressure less than 60, or if 
patients had orthostatic symptoms. 
On day 2, naltrexone treatment was begun. Oral doses were 
given at 9:30 am, 11:30 am, 2:30 pm and 4:30 pm on days 2 and 3. 
The initial dose was 1 mg, increased by 1 mg increments on day 2 
and by 3 mg increments on day 3 if the patient's score on the 17 
point abstinence rating scale was less than 5 prior to the dose 
of naltrexone. On day 4 each patient received 50 mg of naltrex¬ 
one, a maintenance dose. Initially this was administered in 
three divided doses (10 mg at 8-9 am, 15 mg at noon , and 25 mg 
at 5 pm), however 8 patients received the 50 mg in a single oral 
dose at 8-9 am without adverse effects. On day 5 (usually a Fri¬ 
day) patients received 150 mg naltrexone at 8-9 am, and then con¬ 
tinued to receive maintenance doses of naltrexone the following 
week as part of the protocol. Patients came to clinic on days 8, 




Patients with NCT scores (see below) less than 20 in most cas¬ 
es tolerated naltrexone without symptoms, therefore we simplified 
the naltrexone dosage schedule for our last patient. He received 
naltrexone in two daily doses on days two and three, receiving 
doses of 3 mg at 9:30 am and 7 mg at 2:30 pm on day 2, and 12 mg 
at 9:30 am and 24 mg at 2:30 pm on day 3. He did not complain of 
symptoms in response to these doses (his NCT score was 12). 
CONCOMMITANT MEDICATIONS 
Patients were given chloral hydrate, 1 gram p.o. q.h.s., one 
day at a time as indicated for insomnia. For patients who did 
not respond to chloral hydrate, or who experienced muscular ach¬ 
ing not adequately ameliorated by clonidine, flurazepam 30 mg or 
diazepam 10 mg was prescribed in place of chloral hydrate. 
Daily urine samples were collected and analyzed to evaluate 
use of illicit drugs. 
NALOXONE CHALLENGE TEST (NCT) 
Patients not entering the study from a methadone maintenance 
program underwent a naloxone challenge test (NCT). Patients were 
cautioned not to self-administer opioids for eight hours prior to 
the test, which took place between 8 am and 10 am on the morning 
of their first day. 0.8 mg of naloxone was administered i.m. and 
withdrawal symptoms rated using the scale of Wang, et al. (Wang 
1974) (Weisen 1977) (Wang 1982). Wang's rating scale is repro- 
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duced in Table 1. If the patient's predicted score on Wang's 36 
point scale was 9 or more after 10 minutes, clonidine was admin¬ 
istered immediately at 10 minutes. If the patient's predicted 
score was less than 9 after 10 minutes but greater than 9 after 
20 minutes, clonidine was administered at 20 minutes. If the pa¬ 
tient's score was less than 9 after 20 minutes but greater than 0 
after 30 minutes, clonidine was given at 30 minutes. Day 1 clo¬ 
nidine doses, based on NCT scores, are listed in Table 2. Those 
whose withdrawal symptoms were not adequately controlled by their 
initial clonidine dose (score of greater than 5 on our abstinence 
rating scale) received additional clonidine after 60 minutes. 
Individuals whose score was 0 after 10 minutes of the NCT re¬ 
ceived a second injection of 0.8 mg naloxone i.m. and were ob¬ 
served and scored for withdrawal for the following thirty min¬ 
utes. Individuals whose score was less than two 30 minutes after 
having received a total of 1.6 mg naloxone i.m. were told that 
they did not have a clinically recognizable acute withdrawal syn¬ 








20 MIN 30 MIN 




Profuse Sweating 3 
Restlessness 2 




0 2 0 
0 2 0 
0 2 0 
0 2 0 
0 10 















*After Wang, et al (Wang 1974) (Weisen 1977) (Wang 1982). Patients' 
symptoms are rated and points assigned at 10, 20, and 30 minutes. 
Following Wang (Wang 1984a, 1984b), we automatically assigned points 
for later observations if a symptom appeared early, hence symptoms ap¬ 
pearing at 10 minutes gave the subject either 6 or 4 points, symptoms 
first appearing at 20 minutes gave the subject 3 or 2 points. 




Day #1 Clonidine Doses 
PREDICTED NCT SCORE ORAL CLONIDINE HCl (mg) 
(at 10 minutes) 8-10 am 2 pm 8 pm 
>18 0.3 0.1-0.2 0.2 
9-17 0.2 0.1 0.1-0.2 
<9 but >0 0.1-0.2 0.1 0.1 
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MONITORING OF WITHDRAWAL SYMPTOMS AND VITAL SIGNS 
Either an investigator or a research nurse took and recorded 
all data. Vital signs were measured at the start of each study 
day. Sitting and standing blood pressures and heart rate were 
measured before, 60 minutes after, and 120 minutes after each 
clonidine dose. The abstinence rating scale, which rates the 
presence or absence of 17 signs and symptoms of withdrawal, was 
completed by an observer before and 60 minutes after each naltre 
xone dose on days 2 and 3. The patients completed self-rated 
visual analogue scales before and 60 minutes after each naltrex¬ 
one dose. In addition, Spielberger State Anxiety Scales were 
completed by each subject each morning, and each patient complet 
ed the Beck Depression Inventory, the SCL-90, the Spielberger 
Scale and the Rotter Internal/External Locus of Control Scale 
during the week before entrance into the study. 
DATA ANALYSIS 
The number of signs and symptoms reported on the 17 item ab¬ 
stinence rating scale were totaled, and the mean values of this 
score and the analogue scale scores for the ratings completed on 
each day were calculated. These data were used as an index of 
the severity of withdrawal signs and symptoms experienced by the 
patient. For every patient, the percentage of times each indi¬ 
vidual sign or symptoms was rated as present on the abstinence 
rating scale of the total number of ratings completed each day 
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was also calculated to determine the symptoms and signs reported 
most frequently. 
Successful detoxification, defined as completion of the 5 day 
protocol and continued naltrexone maintenance for one week, was 
investigated as a function of maximum discomfort as measured by 
the abstinence rating scale and self-rated analog scales, as well 
as initial depressed mood (Beck Inventory), anxiety level (Spiel- 
berger Scale), locus of control (Rotter Scale), and score on the 
SCL-90. Attrition rates and time of attrition were also analysed 
in terms of the above parameters. Trend curves were constructed 
in which the score on withdrawal scales is plotted against time 
in order to quantify patterns of response. 
NCT scores were correlated with rate of succesful detoxifica¬ 
tion, initial psychological status, maximum daily clonidine and 
naltrexone doses, and level of discomfort as measured by mean 
daily scores on the observer-rated abstinence rating scale and 





Sixteen subjects underwent a NCT. Two had negative challenge 
tests and did not continue in the study. Of the fourteen that 
entered the protocol, twelve successfully completed treatment and 
were discharged on maintenance doses of naltrexone. The two pa¬ 
tients who failed to complete the study were dissimilar. The 
first had a very low NCT score (score of 6 30 min. after 1.6 mg 
naloxone), experienced less discomfort than most patients, but 
failed to appear on the morning of the third day. The second had 
a NCT score of 24, and withdrew from the study at noon on the 
third day because of discomfort. On review it became clear that 
he received less clonidine on day 3 than other patients with high 
NCT scores, and that his symptoms were not as well controlled. 
He may have received inadequate doses of clonidine. The rest of 
the data analysis pertains to the twelve patients who completed 
the protocol. 
One month after they completed the protocol, five of the 
twelve remained in a naltrexone maintenance program, and another 
three claimed to be completely drug free (although their claims 
were not verified by urine toxicology screens). Another subject 
returned to naltrexone maintenance two months after treatment. 
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although he used heroin intermittently following detoxification. 
The remaining three were again using opioids regularly one month 
after completing the protocol; two of them had entered a metha¬ 
done maintenance program. 
No significant correlations were observed between patient 
scores on the psychological tests administered during screening 
and NCT score, degree of discomfort during treatment, or total 
clonidine dose. A nonsignificant correlation was observed be¬ 
tween morning Spielberger State Anxiety Index scores and mean ob¬ 
server-rated abstinence rating scale scores on days 2 and 3 
(r=.60, p<.10; r=.46, p<.20, respectively). No correlation was 
observed between SSAI scores and daily clonidine doses on these 
days (day 2 r=.18, day 3 r=.26). 
NALOXONE CHALLENGE TESTS 
Two of sixteen subjects had negative challenge tests, bearing 
out the need for such provocative testing prior to inclusion in a 
research protocol. Our subjects had a wide range of scores. 
Only two patients required 1.6 mg of naloxone to provoke symp¬ 
toms; most had projected 30 minutes scores greater than 9 10 min¬ 
utes after 0.8 mg naloxone i.m., and received clonidine at that 
time. Because the test was "stopped" after 10 minutes for nine 
subjects, the scores we report may be lower than scores would ac¬ 
tually have been had the test been allowed to run to completion. 
Nevertheless, some of our patients had high scores. In Wang's 
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series of over 200 patients the median score was in the range 
9-12; our median score was 12. 21% of Wang's patients had scores 
over twenty; 28% of our patients had scores over twenty. Wang 
recommends initial methadone maintenance doses of over 70 mg/day 
for these patients. 
CLONIDINE AND NALTREXONE DOSAGE SCHEDULE 
Table 3 lists daily clonidine and naltrexone doses. On day 1, 
patients responded well to clonidine after the NCT, experiencing 
symptom relief thirty minutes after their first p.o. dose. Be¬ 
cause of the NCT, doses were larger than usual clonidine detoxi¬ 
fication doses. 
Clonidine doses rose on days 2 and 3, the first two days of 
naltrexone administration. On these days the three daily doses 
(each of which ranged from 0.1 to 0.3 mg, depending on the pa¬ 
tient's NCT score and response to clonidine on day 1) were sup¬ 
plemented by p.r.n. doses if patients had a score of 5 or greater 
on the abstinence rating scale. These p.r.n. doses were usually 
0.1 or 0.2 mg, and usually were administered after a naltrexone 
dose that had been followed by withdrawal symptoms. Following 
day 3 clonidine doses were tapered rapidly without reemergence of 
withdrawal symptoms or signs. There was a significant correla¬ 
tion (r=.75, p<.01) between NCT score and total clonidine admin¬ 
istered (see figure 1). 
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Many patients experienced a mild increase in withdrawal symp¬ 
toms 30 to 45 minutes following their first dose of 1 mg of nal¬ 
trexone. All patients with NCT scores > 20 experienced an in¬ 
crease in symptoms (more than 5 symptoms on the abstinence rating 
scale) that responded to p.r.n. doses of clonidine. These pa¬ 
tients continued to experience increased symptoms of withdrawal 
following naltrexone doses until their cumulative dose of naltre¬ 
xone exceeded 8 to 10 mg. Following that point no subjects 
claimed to "feel" individual naltrexone doses. 
Patients received between 3 mg and 10 mg of naltrexone on the 
second day, and between 27 mg and 46 mg on the third day. There 
was a significant correlation (r=-.87, p<.01) between NCT score 
and naltrexone tolerated on the second day (figure 2). On the 
fourth day all subjects received at least 50 mg of naltrexone 
without induction of withdrawal symptoms. 
Day 5 was usually a Friday; patients received 150 mg naltrex¬ 
one to ensure opioid blockade over the weekend. One patient did 
not return the following week, but the remaining eleven completed 
an additional week of maintenance naltrexone as part of the pro¬ 
tocol. Of these eleven, one patient had mild "stomach cramps" 
and anorexia on the mornings of naltrexone administration; he 
continued on naltrexone and was asymptomatic after two weeks of 
maintenance. The others had no such symptoms sometimes associat¬ 
ed with naltrexone induction (Martin 1973) (Hollister 1981) (Bra- 




Patients were given chloral hydrate, 1 gram, one dose at a 
time, as needed for insomnia. Eleven patients took at least one 
dose of chloral hydrate. Seven patients complained that chloral 
hydrate did not relieve their insomnia, and received flurazepam, 




Clonidine and Naltrexone Dosage Schedule (Means and SDs) 
Day# Naltrexone HCl, mg/day Clonidine HCl, mg/day 
X SD X SD 
1 0 0 0.5 0.2 
2 8 3 1.1 0.5 
3 40 7 0.6 0.3 
4 50 0 0.3 0.3 
5 150 0 0.2 0.2 
6 0 0.1 0.1 






8* 100 0.0 
10 100 0.0 
12 100 0.0 
* One subject did not return for the second week 
and is not included in days 8, 10, and 12. 
° Two subjects self-administered 0.1 mg clonidine 
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Figure 1 - Total Clonidine vs. NCT Score: Correlates the total 
clondine dose administered to each patient with that patient's 
NCT score. The one patient who completed the protocol who re¬ 
ceived 1.6 mg naloxone during the NCT is excluded, so that all 
NCT scores plotted are for 0.8 mg naloxone, i.m.. Least squares 
regression is shown. r = .75, p < .01 by 2 tailed t test, 9 de¬ 

















mg NALTREXONE, DAY 2 

Figure 2 - Day #2 Naltrexone Dose vs. NCT Score: Correlates the 
total naltrexone dose administered to each patient on day #2 with 
that patient's NCT score. The one patient who completed the pro¬ 
tocol who received 1.6 mg naloxone during the NCT is excluded. 
Least squares regression is plotted. r = -.87, p < .01 by two 
tailed t test, 9 degrees of freedom. Maximum possible naltrexone 
dose on day #2 was 10 mg. 
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SIGNS AND SYMPTOMS OF WITHDRAWAL 
The treatment regimen effectively suppressed signs and symptoms 
of withdrawal. On no day was the mean number of signs and symp¬ 
toms greater than 3 out of the 17 included in the abstinence rat¬ 
ing scale (figure 3). Often the symptoms that were reported were 
mild in nature. Patient ratings of analogue scales (table 4) and 
"withdrawal lines" (figure 4) indicate that the withdrawal pro¬ 
cess was relatively comfortable for the majority of patients. 
The high percentage of patients who completed the protocol sug¬ 
gests that the treatment was efficacious. 
There was a correlation between NOT score and mean number of 
abstinence symptoms. Patients with NOT scores > 20 experienced 
significantly more symptoms, with a mean of over 5 symptoms on 
day 2 (figure 3) (treatment F(l,90)=16.9, pc.Ol). These patients 
experienced a higher degree of subjective discomfort, as evi¬ 
denced by their ratings on the 100 mm "withdrawal line" (figure 
4) (treatment F(1,70)=23.4, pc.Ol). Patients with NCT scores > 
20 reported significantly higher levels of subjective withdrawal 
discomfort on days 2 through 8. The most prominent symptom in 
this group was muscular aching that provoked some distress. The 
final patient to complain of persistent muscular aching was pre¬ 
scribed diazepam 10 mg p.o. b.i.d. (including an evening dose for 
treatment of insomnia) that markedly relieved the symptom. 
For all patients the most persistent symptoms were restless¬ 
ness, anxiety, muscular aching, craving, insomnia, and hot and 
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cold flashes (table 5). From day 5 onward symptoms that were re 
ported were mild. Analogue self-rating scales showed moderate 
positive trends during treatment (table 4). 
Patients were questioned and observed for symptoms and signs 
of a clonidine withdrawal syndrome (Hansson 1975) (Stelzer 1976) 
(Pettinger 1975). No significant "rebound" hypertension was ob¬ 
served when clonidine doses were tapered (table 6). Three pa¬ 
tients did note increased restlessness: one on day 5, another on 
days 4 and 5, and the third on days 5 and 6. All three also not 
ed insomnia on those days, which responded to prescribed medica¬ 
tion. Two of the three said they "felt like I'm speeding;" none 
were distressed by these symptoms, and all reported that their 
symptoms resolved as their clonidine taper was slowed. These 
symptoms could also be explained as opioid withdrawal symptoms 
inadequately treated because the dose of clonidine had been re¬ 












1° 2.8 3.5 3.2 4.0 3.6 2.0 
2 3.2 2.8 2.7 3.2 3.1 1.1 
3 3.2 2.6 2.7 3.3 2.8 1.4 
4 3.6 2.8 3.8 3.3 3.2 1.3 
5 3.4 2.7 3.5 3.0 2.7 0.8 
8 4.1 1.8 5.2 3.3 2.7 0.9 
10 3.5 2.6 4.6 2.9 2.6 1.4 
Changes over time not statistically significant. 
*These scales were rated by patients, using a seven point scale with 
1 as low and 7 as high. 
°Day #1 scales were completed on arrival at clinic, before medications 




Effect of Treatment on 17 Signs and Symptoms of Withdrawal 
DAY # 
NCT 1 2 3 4 5 8 10 12 
Subjective symptoms* 
Craving 92 26 49 29 33 16 25 8 16 
Anxiety 83 21 37 24 19 4 0 0 0 
Restlessness 92 29 41 30 27 38 0 0 0 
Insomnia 75 11 18 8 22 38 8 8 8 
Muscular aching 75 47 53 33 17 25 0 0 0 
Anorexia 92 18 19 18 20 8 0 0 8 
Nausea 75 5 9 2 0 0 0 0 8 
Hot and cold flashes 92 21 31 18 14 8 0 0 8 
Objective symptoms0 
Rhinorrhea 67 5 2 3 0 0 0 0 0 
Tremors 33 3 3 1 0 0 0 0 0 
Perspiration 58 0 9 3 0 0 0 0 0 
Yawning 50 0 1 0 0 0 0 0 0 
Yen for sleep- 42 26 9 12 0 0 0 0 0 
Gooseflesh 100 0 0 0 0 0 0 0 0 
Vomiting 17 3 0 0 0 0 0 0 0 
Diarrhea 8 0 0 2 0 0 0 0 0 
Lacrimation 33 5 1 0 0 0 0 0 0 
Numbers indicate the percentage of positive symptom reports of 
all ratings done each treatment day. Day #1 values include 
all ratings completed two or more hours after NCT. 
^Determined by responses to specific questions. 
determined by direct observation. 





MEAN # OF ABSTINENCE SX AND SIGNS PER DAY 
maximum # of sx and signs = 17 

Figure 3 - # Of Abstinence Symptoms and Signs per Day: Corre¬ 
lates mean number of signs and symptoms per patient per day, as 
rated on the 17 item observer-rated abstinence rating scale, with 
day number. Curves represent mean scores for patients with NCT 
scores > or < 20. The two plots are significantly different as 
analyzed by 2-way ANOVA for repeated measures (treatment 
F(1,90)=16.9, pc.Ol; repeated measure F(9,90)=17.4, pc.Ol; inter¬ 
action F(9,90)=4.5, pc.Ol). The mean score for the NCT > 20 pop¬ 
ulation is significantly different (pc.05) from the NCT c 20 pop¬ 
ulation, by 2-tailed t test, on days 1 through 8, n values as 























A NCT GREATER THAN 20 N=3 
X NCT LESS THAN 20 N=9 

Figure 4 - Mean Withdrawal Line Scores per Day: Correlates mean 
withdrawal line scores with day number. The "withdrawal line" is 
a horizontal 100 mm line that functions as an analogue scale; the 
left end is labelled "0-no withdrawal" and the right end is la¬ 
belled "100-severe withdrawal". Curves represent mean scores for 
patients with NCT scores > or < 20. The two plots are signifi¬ 
cantly different as analyzed by 2-way ANOVA for repeated measures 
(treatment F(1,70)=23.4, pc.Ol; repeated measure F(7,70)=14.8, 
pc.Ol; interaction F(7,70)=3.6, pc.Ol). The mean score for the 
NCT > 20 population was significantly different (p<.05) from the 
NCT < 20 population, by 2-tailed t test, on days 2 through 8, n 
values as listed in the legend. 
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BLOOD PRESSURE AND HEART RATE CHANGES 
Table 6 summarizes changes in blood pressure and heart rate 
during treatment. Clonidine lowered blood pressure significantly 
(treatment F(5,55)~22.0, p<.01 for systolic BP, 12.5, pc.Ol for 
diastolic BP). There were no syncopal episodes during the course 
of treatment, however most patients reported dizziness on stand¬ 
ing during days 2 and 3. Clonidine doses were held or tapered if 
blood pressure fell below 80/60 or if the patient noted orthos¬ 
tatic symptoms; typically, when withdrawal symptoms began to re¬ 
appear, blood pressure increased, and patients were again given 
medication. Dizziness was not present on the fourth day or 
thereafter. Patients with NCT scores > 20 did not have signifi¬ 
cantly larger decreases in blood pressure or heart rate than did 
patients with NCT scores < 20 (treatment F(l,50)=2.99 for systol¬ 
ic BP, 0.4 for diastolic BP). There was no constant relationship 
between NCT score and occurence of orthostatic symptoms. Overall 
fluctuations in standing and supine heart rate were not signifi¬ 
cant (F(5,41)=1.37 for standing heart rate, 1.83 for supine heart 
rate). 
On days 1, 2, and 3, all patients were brought to clinic and 
driven home by a "significant other." Patients were instructed 
to remain home these evenings, to sit when urinating, and not to 
take hot showers. An investigator was "on call" each evening to 
respond to questions. 
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Patients noted sedation on the second and third day, another 
clonidine side effect. This sedating effect is reflected in the 
"yen for sleep" ratings in Table 5. Dry mouth was the other com¬ 
monly reported clonidine side effect. One patient noted a per¬ 




Changes in Standing BP and Pulse during Treatment* 
BP, mm HG HEART RATE, Beats/min 
DAY# systolic diastolic Lying Standing 
X SD X SD X SD X SD 
INITIAL 111 11 74 7 66 9 81 9 
1° 97 # 15 70 13 
2 85 # 13 62 # 10 65 11 81 14 
3 85 # 14 61 # 10 59 7 83 15 
4 97 # 14 68 # 11 68 6 92 # 15 
5 105 13 73 7 73 7 83 13 
8 115 11 78 6 
10 111 13 74 5 
Overall changes in systolic and diastolic BP were significant 
as analyzed by 1-way ANOVA for repeated measures (treatment 
F(5,55)=22.0, pc.Ol for systolic BP, 12.5, p<.01 for diastolic 
BP). Fluctuations in heart rates were not significant (treat¬ 
ment F(5,41)=1.37 for standing heart rate, 1.83 for supine 
heart rate) . 
* Values for each treatment day are the mean (+-SD) for all 
measurements except for "INITIAL", which is the mean for all 
subjects of two BP measurements taken at least three days 
apart prior to each subject's entry into the study. 
Initial heart rates are measurements from morning of day #1, 
prior to medication or NCT. 
# Significantly different from "INITIAL" (pc.Ol) by two tailed 
t test, with n=24 for INITIAL BP means and n=ll for heart 
rate means. 
° Measurements are included that were > two hours after NCT. 
-■ Standing measurements reflect orthostatic effects; supine 
measurements were used to eliminate orthostatic effects and 




Subjects appeared to comply well with instructions regarding 
clonidine self-administration. They were given one day's (or 
evening's) supply of clonidine on leaving clinic, and they re¬ 
turned pill bottles each morning and accounted for all clonidine 
taken. Usually patients were given 0.1 mg to 0.3 mg clonidine 
for p.r.n. use, in addition to prescribed doses; several pa¬ 
tients consistently woke in the early morning hours with with¬ 
drawal symptoms that responded to a p.r.n. dose of clonidine. 
One patient self-administered intravenous heroin and cocaine 
on the evening of the first day, and another used intravenous 
heroin on the second evening. They were allowed to continue in 
the protocol; both received maximum doses of naltrexone without 
adverse effects, and had low mean abstinence rating scale scores 
Both had initial NCT scores < 20. All patients had urine toxi¬ 
cology screens sent on the first, third, and fifth mornings. 
These were unremarkable, except for the two incidents mentioned. 
Another subject self-administered intravenous heroin on the sev¬ 
enth day, when he had already taken maintenance doses of naltrex 




The one subject who entered the study from methadone mainte¬ 
nance had a difficult course and did not complete the protocol. 
She had been maintained on methadone for two years, and used a 
TENS unit for treatment of back pain following an automobile ac¬ 
cident one year prior to entering our protocol. Her daily metha¬ 
done dose (originally 80 mg) had been rapidly tapered to 25 mg, 
and she was very anxious about detoxifying, but wanted to try it 
so that her fiance would not know she was on methadone mainte¬ 
nance. Her withdrawal symptoms were not adequately controlled, 
despite clonidine doses in excess of previously published dosage 
ranges established by the Connecticut Mental Health Center inpa¬ 
tient clonidine-naltrexone protocol (Charney, et al, 1982). On 
the evening of the second day she withdrew from the study, having 
received 3 mg naltrexone and 3.0 mg clonidine by 6 pm. At that 
time her standing blood pressure was 118/88, with a pulse rate of 
60. She received 20 mg methadone and presented 4 hours later 
with headache, a pulse of 27 beats per minutes, and a systolic 
blood pressure of 180. EKG showed irregular sinus bradycardia 
without heart block or escape rhythms. Optic discs were flat and 
sharp, and neurological examination was nonfocal. She did not 
report withdrawal symptoms. She was subsequently hospitalized 
and observed until her pulse rate and blood pressure returned to 
normal; no medical treatment was required. Retrospectively she 
reported that she had been taking large doses of Darvocet (ob¬ 
tained by prescription for relief of back pain) at home during 
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the past month, to relieve discomfort associated with methadone 
taper. She also reported that she had ingested 150 mg illicitly 
obtained flurazepam on the evening of day 1, and flurazepam, dia¬ 
zepam, and Darvocet tablets on the evening of day 2 after receiv¬ 
ing methadone. Bradycardia and hypertension are symptoms of clo- 
nidine overdose (Andserson 1981) (Rotellar 1981), and the 
patient's course was consistent with clonidine effect unopposed 
by withdrawal following methadone administration, but the large 
self-administered doses of benzodiazapenes (as well as opioids, 
and possibly other compounds) cloud interpretation of the event. 
This experience highlights the potential problem of patients' 
self-administering large doses of illicit medications during out¬ 
patient treatment. Other candidates have yet to enter our proto¬ 
col from methadone maintenance; such patients have been success¬ 






This clonidine-naltrexone regimen enabled 12 of 14 heroin 
users to completely withdraw from opioids in 5 days, while simul¬ 
taneously initiating naltrexone maintenance. This success rate 
of 86% compares favorably to previous experience with gradual me¬ 
thadone taper (13 out of 24 patients, 35%) (Dorus 1981) and 
treatment with clonidine alone (4 out of 11 patients, 36%) (Wash- 
ton 1980b). It is comparable to the experience of Charney, et al 
(Charney 1982) who used a similar regimen with 11 inpatients. 
Comparison with this earlier study, which used identical rating 
scales, generally reveals a lesser incidence of symptoms in the 
current study; all patients in the earlier study were withdrawn 
from methadone maintenance. 
Since our protocol simultaneously began naltrexone mainte¬ 
nance, the 86% who completed the protocol also successfully began 
naltrexone maintenance therapy. Only one of the twelve experi¬ 
enced symptoms sometimes associated with the first 10 days of 
naltrexone treatment (Brahen 1977). This rate of successful nal¬ 
trexone induction compares well to previously published studies 
which report successful induction rates of non-opioid dependent 
outpatients ranging from 37% to 50% (Callahan 1976) (Resnick 
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1980) (Kosten 1984). Our data support the previously suggested 
hypothesis that clonidine may be an effective adjunct to initia¬ 
tion of naltrexone maintenance, even for those outpatients who 
are no longer opioid dependent (Kosten 1984) (Dorus 1982). 
Clonidine and naltrexone worked well in the outpatient set¬ 
ting. Patients reported mild withdrawal symptoms that did not 
interfere with treatment. Signs of opioid withdrawal were rarely 
seen. While patients felt "under the weather" on days 2 and 3, 
on days 4 and 5 they rarely had significant complaints. Standing 
blood pressures were lowered, often producing some orthostatic 
symptoms on days 2 and 3 without clinical problems. Flexible 
dosage schedules allowed us to tailor individual treatment so as 
to minimize symptoms of withdrawal. 
Limitations on outpatient treatment emerged. Of the two pa¬ 
tients who withdrew from the study, one was relatively asympto¬ 
matic; perhaps this subject would have remained in treatment had 
he been hospitalized and removed from the mileu of drug abuse. 
In addition, one patient was hospitalized and observed for signs 
of clonidine overdose following her withdrawal from the study, 
administration of methadone, and self-administration of opioids 
and benzodiazapenes. Although this patient did not require medi¬ 
cal treatment, her case illustrates the potential risks of con¬ 
current illicit drug use. Patients who leave a clonidine-naltre¬ 
xone regimen before receiving enough naltrexone to establish 
opioid blockade, and who subsequently receive opioids, may devel- 
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op signs of clonidine overdose if they have been given large dos¬ 
es of clonidine. Thus large daily doses of clonidine (> 3.0 rag 
over 24 hr) should be administered with caution to outpatients, 
especially if they are likely to withdraw from treatment and re¬ 
sume opioid use prior to receiving blockading doses of naltrex¬ 
one. Two other subjects who completed the protocol used illicit 
drugs intercurrently, apparently not affecting the course of 
their treatment. 
The patient who experienced medical complications came to our 
protocol from methadone maintenance. Given the results of Char- 
ney, et al, who successfully treated methadone maintained pa¬ 
tients with a similar clonidine-naltrexone regimen (Charney 
1982), the poor control of this patient's symptoms was probably 
not a function of her previous methadone maintenance, but rather 
of her anxiety and illicit drug use. Nevertheless, outpatient 
treatment of methadone maintained patients with this regimen re¬ 
quires additional investigation. 
Naloxone challenge tests established that patients were indeed 
dependent on opioids. Two subjects (12%) had a negative NCT. 
One of these two subjects had claimed to use large quantities of 
heroin daily and was expected to have a high score; following the 
test he admitted that he actually used much smaller amounts of 
opioids. Previously reported incidences of negative challenge 
tests range from 3% (Blachly 1973) to 33% (Judson 1980). 
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Correlations were observed between NCT score and total cloni- 
dine administered, patient discomfort as measured by patient-rat¬ 
ed analogue "withdrawal lines", and patient discomfort as meas¬ 
ured by the observer-rated abstinence rating scale. An inverse 
correlation was observed between NCT score and day 2 naltrexone 
doses. These findings suggest that the clonidine-naltrexone reg¬ 
imen most effectively suppresses withdrawal symptoms in less se¬ 
vere addictions. However, even patients with NCT scores over 20 
(who are the 20% with the most severe addictions in Wang's se¬ 
ries) (Weisen 1977) (Wang 1982) tolerated the protocol, generally 
experiencing more symptoms and receiving naltrexone in a more 
gradual fashion. These patients had more symptoms of withdrawal 
despite receiving higher doses of clonidine. This suggests either 
that clonidine in non-toxic doses has a limited capacity to slow 
central noradrenergic activity during precipitated withdrawal, or 
that other central and peripheral effects of opioids (Redmond 84) 
can provoke withdrawal symptoms not associated with noradrenergic 
activity. Diazepam appeared to be of use in ameliorating the 
persistent muscle tension and aching that was the most prominent 
symptom experienced by these patients. (An alternative explana¬ 
tion of these findings is that the severity of the symptoms en¬ 
countered by the patient during the NCT affected their expecta¬ 
tions for the subsequent withdrawal process and so altered their 
subjective experience. This hypothesis would not, however, ac¬ 
count for these patients' need for higher clonidine doses or more 
gradual naltrexone introduction.) 
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If this regimen is employed without a NCT, day 1 clonidine 
doses will be lower, and subsequent clonidine and naltrexone dos¬ 
es must be titrated to patient symptoms with p.r.n. clonidine 
doses on days 2 and 3, as outlined in the "methods" and "results" 
sections. Alternatively, naltrexone could be begun on the first 
day, following an initial clonidine dose of 0.1 to 0.3 mg in the 
morning, shortening the protocol by one day. The naloxone admin¬ 
istered during the NCT, by inducing abrupt withdrawal, may have 
had a theraputic as well as diagnostic effect. This effect was 
probably small given the short half-life of naloxone. 
Why does naltrexone speed the time course of withdrawal, en¬ 
abling patients to discontinue clonidine by their sixth day of 
treatment? As outlined in the introduction, administration of 
naltrexone to opioid-dependent animals rapidly reverses morphine- 
induced increases in the number of brain alpha-2 and beta adren¬ 
ergic binding sites (Cedarbaum 1977) (Hamburg 1981). In addi¬ 
tion, clonidine suppresses naltrexone-precipitated withdrawal 
signs and symptoms, but increased doses of clonidine are required 
(Charney 1981) (Charney 1982). Thus naltrexone probably speeds 
the process of withdrawal by rapidly reversing opioid-induced 
central noradrenergic hypersensitivity. Interestingly, patients 
withdrawing from heroin required clonidine until their fifth or 
sixth day, as did patients withdrawing from methadone in the in¬ 
patient study of Charney, et al (Charney 1982). A clonidine-nal- 
trexone protocol appears to equalize the length of the heroin and 
methadone withdrawal syndromes, possibly by displacing opioids 
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from binding sites and so eliminating the effect of opioid half- 
life on the time course of central noradrenergic renormalization. 
Naltrexone also increases opioid receptor number and functional 
sensitivity (Lahti 1978) (Schulz 1979), and might reverse the hy¬ 
pothesized exogenous opioid-induced deficiency in endogenous 
opioid function (Kosterlitz 1975) (Goldstein 1977). This action 
could account for rapid resolution of withdrawal symptoms in this 
context, but only if the degree of opioid blockade achieved with 
50 mg naltrexone per day does not block endogenous opioid ac¬ 
tions. Acutely, 50 mg naltrexone blocks the effects of as much 
as 240 mg morphine (Martin 1973), and tolerance to naltrexone's 
antagonistic effect does not develop after chronic administration 
(Kleber 1985). 
IMPLICATIONS 
This study demonstrates that a clonidine-naltrexone regimen is an 
effective, safe, and rapid means of treating heroin withdrawal in 
a supervised outpatient/day setting. The protocol we have used 
requires patient visits to clinic on the mornings of days 1, 4, 
and 5, and patient presence in clinic on days 2 and 3. It also 
prevents patients from working or driving on the first two days 
of naltrexone administration. 
Naltrexone was approved by the Food and Drug Administration in 
November 1984, and is marketed under the trade name of "Trexan." 
Thus this technique can be more widely used for heroin detoxifi¬ 
cation (although clonidine is still an experimental treatment of 
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opioid withdrawal). Trexan is supplied in scored 50 mg tablets, 
therefore use of the protocol described in this paper would re¬ 
quire preparation of "powder packets" of pulverized tablets. Al¬ 
ternatively, tablets could be fractured twice and an initial dose 
of 12.5 mg naltrexone given. We have not administered an initial 
dose larger than 3 mg. However, patients with NCT scores below 
20 (and certainly those with scores below 15) have, in general, 
tolerated their initial doses of naltrexone so well that a first 
dose of 12.5 mg is conceivably appropriate for them. If this 
larger dose was used, naltrexone could be administered in one or 
two daily doses on days 2 and 3, and patients could leave clinic 
earlier on these days, as well. Investigation of a simplified 
protocol, and treatment of methadone maintained patients with an 
outpatient protocol, are the next logical steps for this outpa¬ 
tient research. 
This protocol provided 11 of 12 patients with a simultaneous 
smooth induction of naltrexone maintenance, and no patients noted 
symptoms of a prolonged abstinence syndrome during the week fol¬ 
lowing treatment. The possible value of this treatment method in 
improving the long-term prognosis of opioid abusers awaits inves¬ 
tigation in well controlled studies comparing clonidine and nal¬ 
trexone to clonidine alone and slow methadone taper. The time 
course and patient comfort of this regimen make it a useful, at¬ 
tractive, and efficacious outpatient method of treating the acute 
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